Navigation Links
12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system)

t common psychiatric disorders in children and adolescents. ADHD is a neurobiological psychiatric disorder that manifests as a persistent pattern of inattention and/or hyperactivity- impulsivity that is more frequent and severe than is typically observed in individuals at a comparable level of development. To be properly diagnosed with ADHD, a child needs to demonstrate at least six of nine symptoms of inattention; and/or at least six of nine symptoms of hyperactivity/impulsivity; the onset of which appears before age 7 years; that some impairment from the symptoms is present in two or more settings (e.g., at school and home); that the symptoms continue for at least six months; and that there is clinically significant impairment in social, academic or occupational functioning and the symptoms cannot be better explained by another psychiatric disorder.

Although there is no "cure" for ADHD, there are accepted treatments that specifically target its symptoms. The most common standard treatments include educational approaches, psychological or behavioral modification, and medication.

Shire ADHD Portfolio

Shire's portfolio of ADHD treatments includes VYVANSE(TM) (lisdexamfetamine dimesylate), the first prodrug stimulant, which is planned to launch June 2007, DAYTRANA(TM) (methylphenidate transdermal system), the first and only ADHD patch, and ADDERALL XR(R) (mixed salts of a single-entity amphetamine product), a long-acting formulated stimulant. Additional ADHD treatments under development by Shire include SPD465 (triple-bead mixed amphetamine salts) and SPD503 (guanfacine HCl extended release).

    For further information please contact:


    Porter Novelli for Shire


    Marion E. Glick

    212.601.8273

    917.301.4206 (on site at APA)

    


    Jennifer Anello

    212.601.8132

    203.470.0836 (on site at APA)

    


    APA# NR664

    May 23, 2007; 12:00 p.m. PDT (3:00 p.m. EDT)

    Sails Pavilion, Upper Level, San Diego Con
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
(Date:7/25/2014)... , July 25, 2014  In today,s marketplace, ... costly and challenging - as is managing a portfolio ... Is it possible - or even preferable - ... so, where can you combine resources and activities, and ... These are just a few of the ...
(Date:7/25/2014)... , July 25, 2014 /PRNewswire-iReach/ -- ScriptPro, of ... of Powers Lake, Wisconsin , ... a distribution and co-marketing agreement allowing ScriptPro to ... throughout the United States . ... management and workflow systems to retail and ambulatory ...
(Date:7/25/2014)... , July 25, 2014  The Chemistry, Food ... Ministry of Health approved the introduction of Telaprevir ... the cure rate from Hepatitis C, and it ... 1 virus. Telaprevir is available in ... Photo - http://www2.prnewswire.com.br/imgs/pub/2014-07-25/original/2026.jpg   ...
Breaking Medicine Technology:Using Promotional Efficiency to Support Multiple Products and Indications in the Pharmaceutical Marketplace 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 3The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3
... Filtrona Porous Technologies, a custom developer and manufacturer ... to absorb, retain, transfer, filter or release fluids ... polyurethane foams and bonded fibers at the MEDICA ... 17 to 19 November 2010. ...
... Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics ... Moch, President and Chief Executive Officer, will present at ... Wednesday, November 17, 2010, 10:30 a.m. ET, at the ... Mr. Moch will give an update on the company,s ...
Cached Medicine Technology:Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference 2
(Date:7/28/2014)... According to the Greek God Muscle Building Program review ... that teaches men how to completely transform their physique by ... its review that inside the Greek God Muscle Building Program ... gain the maximum muscle fiber recovery , ... gain , Ways to incorporate the specialization routines ...
(Date:7/28/2014)... 28, 2014 To commemorate World Hepatitis ... of Living with a Disability magazine has ... disorders that include hepatitis, gastrointestinal hemorrhage, inflammatory bowel disease, ... important new article highlights that, in the context of ... hepatitis and other disabling conditions related to the digestive ...
(Date:7/28/2014)... 28, 2014 Greta Pontarelli, 63, won her ... Champion title at the World Pole Sports Championships in London ... this athlete. She is the only U.S. competitor to qualify, ... Pole Sports Federation (IPSF). Over 150 athletes ranging in age ... in the competition. Pontarelli scored first place in the Masters ...
(Date:7/27/2014)... 28, 2014 Zensah®, the leader in compression ... include a wrist support . The wrist support features ... area. , Lateral and Medial Epicondylitis, more commonly referred to ... which there is inflammation of the tendons attached to the ... wrist pain, the muscles that work the wrist and fingers ...
(Date:7/27/2014)... regimens could provide shorter, more effective treatment options with ... with hepatitis C, even those most difficult to treat, ... The Lancet . , Both studies focused on ... genotype in the USA, Europe, North Asia, Australia, and ... treat. , Around 150 million people worldwide have chronic ...
Breaking Medicine News(10 mins):Health News:Greek God Muscle Building Program Review Exposes Greg O’Gallagher's Muscle Building Guide for Men – Vkool.com 2Health News:Greek God Muscle Building Program Review Exposes Greg O’Gallagher's Muscle Building Guide for Men – Vkool.com 3Health News:Living with a Disability Magazine Marks World Hepatitis Day on July 28 with New Article on Disabling Digestive Disorders 2Health News:Living with a Disability Magazine Marks World Hepatitis Day on July 28 with New Article on Disabling Digestive Disorders 3Health News:Inspiring Senior Athlete Lands Third World Title in One Year 2Health News:Zensah® Releases New Wrist Support 2Health News:The Lancet: New oral drug regimens cure hardest-to-treat hepatitis C 2Health News:The Lancet: New oral drug regimens cure hardest-to-treat hepatitis C 3
... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today announced it ... 5, 2009. In conjunction, the Company will host a conference call at ... update. , , Date: ... Conference call access:, Internet: www.istavision.com, ...
... KALAMAZOO, Mich., July 29 Stryker Corporation (NYSE: ... Directors to nine and the election of Dr. Srikant M. Datar as ... Associate Dean and Director of Research at the Graduate School of Business ... at Harvard University since joining that organization in 1996. , , ...
... , , , , ... a worldwide leader in the development, distribution and use of ... $5 million financing commitment from Toronto-based MMV Financial ("MMV"). ... on-going cutting-edge clinical research, including immunotherapy and focal therapy, for ...
... ... of being overbilled, double-billed or billed for expenses they didn,t incur. , ... Norwalk, CT (PRWEB) July 29, 2009 -- ccording ... role in fully half of all U.S. foreclosures. CreditFYI, an educational consumer website on ...
... , , NEW YORK, July ... Cristie Kerr in 2003 with a mission to raise funds and ... classic will be held at Liberty National. The event, on Friday, ... a dinner reception and poker tournament. Renowned celebrity chef Todd ...
... North Carolina are reporting assembly of the first functioning ... inside cells helps process and package hormones, enzymes, and ... The lab-on-a-chip device could lead to a faster and ... or blood thinner, the researchers note. Their study is ...
Cached Medicine News:Health News:Stryker Announces Election of New Director 2Health News:US HIFU Secures $5 Million Financing From MMV Financial 2Health News:US HIFU Secures $5 Million Financing From MMV Financial 3Health News:As Medical Bills Contribute to 50% of U.S. Foreclosures, CreditFYI Shares 5 Tactics for Managing Medical Debt 2Health News:Birdies for Breast Cancer Announces Fifth Annual Charity Golf Classic Hosted by Top Women's Golfer, Cristie Kerr 2
Flattened points in vertical plane, straight shafts, cross action, round handle....
Karate chopper, spear shaped for ease of insertion into the nucleus....
Round serrated handle, dull finish....
Specially designed wider jaws to help split soft nucleus, cross action, round handle, maximum opening 2.8 mm....
Medicine Products: